Gary F Lewis Selected Research

VLDL Lipoproteins

1/2020	Role of the Gut in Diabetic Dyslipidemia.
12/2013	High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men.
4/2012	Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes.
8/2002	Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction.
8/2002	Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster.
1/2002	Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance.
1/2002	The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gary F Lewis Research Topics

Disease

39	Insulin Resistance 01/2021 - 01/2002
27	Type 2 Diabetes Mellitus (MODY) 01/2020 - 01/2002
17	Dyslipidemias (Dyslipidemia) 10/2022 - 01/2002
16	Hypertriglyceridemia 01/2020 - 01/2002
14	Hyperlipidemias (Hyperlipidemia) 01/2018 - 06/2004
12	Cardiovascular Diseases (Cardiovascular Disease) 10/2022 - 12/2002
11	Obesity 01/2021 - 01/2002
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 11/2004
7	Atherosclerosis 01/2022 - 06/2005
7	Hyperinsulinism (Hyperinsulinemia) 01/2016 - 04/2002
6	Hyperglycemia 01/2020 - 04/2002
6	Inflammation (Inflammations) 01/2016 - 08/2007
5	Overweight 01/2018 - 11/2009
3	Hypoglycemia (Reactive Hypoglycemia) 02/2021 - 11/2012
3	Body Weight (Weight, Body) 01/2015 - 05/2008
2	Infections 02/2021 - 09/2015
2	Prediabetic State (Prediabetes) 01/2021 - 01/2020
2	Glucose Intolerance 01/2021 - 03/2010
2	Malnutrition (Nutritional Deficiencies) 12/2016 - 09/2015
2	Weight Loss (Weight Reduction) 02/2016 - 12/2010
2	Bipolar Disorder (Manic Depressive Psychosis) 11/2012 - 08/2007
2	Weight Gain 06/2012 - 12/2004
1	Non-alcoholic Fatty Liver Disease 01/2022
1	Vascular Diseases (Vascular Disease) 01/2022
1	Ischemic Stroke 12/2021
1	Aortic Valve Stenosis (Aortic Stenosis) 12/2021
1	Myocardial Infarction 12/2021
1	Diabetes Complications 02/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2016
1	Fatty Liver 12/2016
1	Hypoalbuminemia 12/2016
1	Familial Combined Hyperlipidemia (Combined Hyperlipidemia, Familial) 02/2015

Drug/Important Bio-Agent (IBA)

34	Insulin (Novolin)FDA Link 01/2021 - 01/2002
25	Lipoproteins (Lipoprotein)IBA 12/2021 - 01/2002
17	Triglycerides (Triacylglycerol)IBA 12/2021 - 01/2002
17	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2002
13	LipidsIBA 10/2022 - 11/2004
11	Nonesterified Fatty Acids (NEFA)IBA 01/2021 - 04/2002
7	ChylomicronsIBA 01/2020 - 01/2002
7	VLDL LipoproteinsIBA 01/2020 - 01/2002
7	HDL CholesterolIBA 01/2018 - 01/2002
6	FructoseIBA 05/2013 - 01/2002
5	oxidized low density lipoproteinIBA 01/2022 - 12/2002
5	ApolipoproteinsIBA 01/2022 - 09/2003
5	Apolipoprotein B-48IBA 02/2016 - 08/2002
5	Rosiglitazone (Avandia)FDA Link 05/2008 - 08/2002
4	CholesterolIBA 01/2022 - 06/2005
4	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 11/2009
4	HDL LipoproteinsIBA 01/2018 - 09/2003
4	IncretinsIBA 07/2015 - 01/2009
3	LDL CholesterolIBA 01/2018 - 02/2015
3	Glucagon-Like Peptide-1 Receptor AgonistsIBA 07/2015 - 09/2010
3	phospholipid emulsion soybean oil (Intralipid)IBA 10/2011 - 03/2010
3	Heparin (Liquaemin)FDA LinkGeneric 10/2011 - 03/2010
2	Hormones (Hormone)IBA 01/2020 - 01/2015
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2018 - 09/2003
2	Apolipoprotein C-IIIIBA 03/2017 - 09/2008
2	Apolipoprotein B-100 (Apo B 100)IBA 02/2016 - 12/2013
2	Saline SolutionIBA 01/2016 - 03/2010
2	Proteins (Proteins, Gene)FDA Link 09/2015 - 12/2004
2	Dipeptidyl-Peptidase IV InhibitorsIBA 07/2015 - 12/2012
2	AntioxidantsIBA 01/2013 - 10/2011
2	Lipase (Acid Lipase)FDA Link 07/2008 - 11/2004
2	C-PeptideIBA 02/2007 - 06/2002
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2006 - 12/2002
1	eicosapentaenoic acid ethyl esterIBA 01/2022
1	ruxolitinibIBA 01/2022
1	Liver X ReceptorsIBA 01/2022
1	Antihypertensive Agents (Antihypertensives)IBA 01/2022
1	Apolipoproteins E (ApoE)IBA 01/2022
1	Janus Kinase 2IBA 01/2022
1	Glycerol (Glycerine)FDA LinkGeneric 01/2021
1	PalmitatesIBA 01/2021
1	LeptinIBA 01/2020
1	Biological ProductsIBA 01/2020
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020
1	Insulin Lispro (Humalog)FDA Link 01/2018
1	Adenosine Triphosphate (ATP)IBA 12/2016
1	RNA (Ribonucleic Acid)IBA 01/2016
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	Niacin (Nicotinic Acid)FDA LinkGeneric 01/2016
1	Nucleic AcidsIBA 01/2016
1	Fibric Acids (Fibrates)IBA 01/2016
1	Cholesterol Ester Transfer ProteinsIBA 01/2016
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2016
1	LipopolysaccharidesIBA 09/2015
1	Glucagon-Like Peptides (Enteroglucagon)IBA 07/2015
1	CarbohydratesIBA 07/2014
1	Sitagliptin Phosphate (Januvia)FDA Link 07/2014
1	Dietary SugarsIBA 07/2014
1	Chylomicron RemnantsIBA 04/2014

Therapy/Procedure

10	Therapeutics 01/2022 - 01/2005
4	Bariatric Surgery 03/2017 - 10/2014
2	Glycemic Control 01/2020 - 02/2016
2	Protein-Restricted Diet (Diet, Protein Restricted) 12/2016 - 09/2015
2	Highly Active Antiretroviral Therapy (HAART) 01/2005 - 10/2002
1	Secondary Prevention 01/2022
1	Surgical Amputation (Amputations) 02/2021
1	Intranasal Administration 01/2018
1	Intravenous Infusions 01/2016